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Introduction: Acute convulsions in children are a common emergency worldwide. Benzodiazepines are the recommended ﬁrst line treatment. Intravenous lorazepam is
inexpensive, long acting and the ﬁrst line drug in resource-rich settings. However, comparable efﬁcacy by other routes of administration is unknown. We wished to
compare the efﬁcacy of lorazepam by the buccal, intranasal or intravenous route in the treatment of acute seizures in Malawian children.
Methods: A prospective, open-label, randomised, non-inferiority trial was performed in children aged 2 months to 14 years presenting to the Queen Elizabeth Central
Hospital in Blantyre, Malawi with acute seizures lasting longer than 5 min. Children were randomly assigned to receive lorazepam, 0.1 mg/kg, by the buccal, intranasal
or intravenous route. The primary endpoint was seizure cessation within 10 min of drug administration.
Results: There were 761 seizures analysed, with 252 patients in the buccal, 245 in the intranasal and 264 in the intravenous groups. Intravenous lorazepam stopped
seizures within 10 min in 83%, intranasal lorazepam in 57% (RR 2.46, CI 1.82–3.34), and the buccal route in 46% (RR 3.14, CI 2.35–4.20; p= 0.001) of children. There
were no signiﬁcant cardio-respiratory events and no difference in mortality or neurological deﬁcits. The study was halted after an interim analysis showed that the
primary endpoint had exceeded the protocol-stopping rule.
Conclusions: Intravenous lorazepam effectively treats most childhood seizures in this setting. Intranasal and buccal routes are less effective but may be useful in pre-
hospital care or when intravenous access cannot be obtained. Further studies comparing intranasal lorazepam to other benzodiazepines, or alternative doses by a non-
intravenous route are warranted.Introduction: dans le monde entier, les convulsions aigues constituent une urgence fre´quente. Il est recommande´ d’utiliser des benzodiaze´pines en traitement de pre-
mie`re intention. Le loraze´pam administre´ par voie intraveineuse est peu couˆteux, a une action prolonge´e, et constitue le traitement de premie`re intention dans les re´gions
riches en ressources. L’efﬁcacite´ comparable de ce traitement par d’autres voies d’administration est cependant inconnue. Nous souhaitions comparer l’efﬁcacite´ du
loraze´pam par voie orale, intranasale ou intraveineuse dans le traitement des attaques aigue¨s chez les enfants au Malawi.
Me´thodes: Une e´tude prospective, ouverte, randomise´e et de non infe´riorite´ a e´te´ re´alise´e sur des enfants aˆge´s de deux mois a` 14 ans se pre´sentant a` l’hoˆpital central
Queen Elizabeth a` Blantyre, au Malawi, souffrant d’attaques aigue¨s de plus de cinq minutes. Les enfants e´taient re´partis de manie`re ale´atoire pour se voir administrer
0.1 mg/kg de loraze´pam par voie orale, intranasale ou intraveineuse. Le point ﬁnal primaire e´tait l’interruption de l’attaque dans les 10 min suivant l’administration du
me´dicament.
Re´sultats: 761 attaques ont e´te´ analyse´es, dont 252 patients dans le groupe d’administration par voie orale, 245 dans le groupe d’administration par voie intranasale et
264 dans le groupe d’administration par voie intraveineuse. Le loraze´pam administre´ par voie intraveineuse arreˆtait les attaques dans les 10 min dans 83% des cas, le
loraze´pam administre´ par voie intranasale dans 57% des cas (RR 2,46, IC 1,82–3,34), et le loraze´pam administre´ par voie orale dans 46% des cas (RR 3,14, IC 2,35–
4,20; p = 0,001). Aucun e´ve´nement cardio-respiratoire signiﬁcatif n’a e´te´ enregistre´, et aucune diffe´rence n’a e´te´ rapporte´e dans les taux de mortalite´ ou de´ﬁcits neu-
rologiques. L’e´tude a e´te´ interrompue apre`s qu’une analyse inte´rimaire a indique´ que le point ﬁnal primaire avait de´passe´ la re`gle d’interruption du protocole.
Buccal, intranasal or intravenous lorazepam for the treatment of acute convulsions 121Conclusions: Le loraze´pam administre´ par voie intraveineuse traite efﬁcacement la plupart des attaques dont les enfants sont victimes dans cet environnement. Les
voies intranasale et orale sont moins efﬁcaces mais peuvent s’ave´rer utiles dans les soins pre´hospitaliers ou lorsqu’un acce`s par voie intraveineuse est impossible.
Des e´tudes supple´mentaires comparant le loraze´pam intranasal a` d’autres benzodiaze´pines, ou a` d’autres doses par voie intraveineuse, sont recommande´es.African relevance
 Control of seizures is highly relevant to African paediatric
emergency care.
 The cost and ease of delivery of medications is important in
resource restricted health care settings.
Introduction
Acute convulsions are a common medical emergency in chil-
dren worldwide.1,2 Rapid and effective treatment is essential;
the longer a convulsion lasts the more difﬁcult it is to termi-
nate.3–6 Prolonged convulsions (>30 min) are associated with
signiﬁcant morbidity and mortality.7–9 Access to emergency
care in resource-constrained countries is uneven and patients
often present late: health centres may have only basic facili-
ties.10 An effective, safe, inexpensive, long acting and easy to
administer anti-convulsant is required.
Benzodiazepines are effective ﬁrst line anti-convulsants.
Therapeutic options include diazepam, lorazepam or midazo-
lam, which have different pharmacokinetic properties.
Historically, diazepam has been used; it is widely available,
inexpensive and acts rapidly but it is short acting, break-
through seizures are common and can cause respiratory
depression.11–14
Midazolam can be given by buccal, intranasal and intra-
muscular routes. Buccal midazolam is as effective as rectal dia-
zepam7,15–18 but it is short acting19 and consequently
associated with seizure recurrence.16,20
Lorazepam is inexpensive,21 long acting (up to 72 h)22 and
has less risk of seizure recurrence.23 Refrigerated lorazepam
has a shelf life of 3 years.21 Stored at 15–30 C, it retains 90%
of its original concentration for 150 days.24,25 At >30 C,
stocks have to be replenished every 30–60 days. It can be given
intravenously (IV), intramuscularly (IM), buccally or intrana-
sally (IN). Intravenous lorazepam (100 lg/kg) is recommended
as ﬁrst line treatment of acute childhood seizures in resource-
rich settings when IV access is available.26–29 However, IV
access can be problematic. Intranasal lorazepam (100 lg/kg)
was effective and safe in treating children with protracted con-
vulsions in Malawi30; it is well absorbed, with rapid action
and comparable elimination proﬁles to IM and IV routes.31 A
2 mg dose achieves concentrations above therapeutic levels in
adults.32 Sublingual/oral lorazepam is absorbed more slowly
but has successfully controlled seizures in children.33
We compared the efﬁcacy of lorazepam when given by the
buccal, intranasal or intravenous route in the treatment of
acute seizures in Malawian children.
Methods
This was an open-label, randomised, non-inferiority trial with
the hypothesis that buccal and/or IN lorazepam were non-
inferior in efﬁcacy to IV lorazepam. The study was carriedout at Queen Elizabeth Central Hospital (QECH) in
Blantyre, Malawi, a tertiary government hospital for southern
Malawi and district hospital for Blantyre district. The paedi-
atric emergency centre (EC) reviews 80–90,000 children annu-
ally of whom 25,000 are admitted. During the rainy season the
number of admissions is high with mainly infectious diseases
such as malaria, gastroenteritis and pneumonia. Children are
stabilised in the EC. Acutely ill children are admitted to high
dependency areas in the acute care wards. Seizures are man-
aged in all these sites. Children (2 months to 14 years) with
acute generalised seizures P5 min were eligible for inclusion.
Seizures were deﬁned as rhythmic twitching of the arms, legs,
trunk or facial muscles, tonic eye deviation, or nystagmoid
eye jerking in a comatose child. Patients were eligible for re-
recruitment if they had further seizures and had not received
anti-convulsants within the previous hour.
Convulsing children were managed according to Advanced
Paediatric Life Support guidelines (except that in Malawi IM
rather than rectal paraldehyde is used) and hypoglycaemia
was corrected.28 Continuing seizures received one of the fol-
lowing: 100 lg/kg of lorazepam (Ativan, Wyeth-Ayerst,
Philadelphia, USA) by slow IV injection followed by a 0.9%
2 ml saline ﬂush, rapid intranasal delivery using a mucosal
atomisation device (MAD 100, wolfetory.com) closely applied
to one nostril and angled upwards with the child’s head in the
recovery position, or a buccal solution injected directly from a
1 ml syringe between the lower gum and cheek that was then
massaged. The IV solution of lorazepam was used for all
routes.
If seizures continued at 10 min, a second similar dose by the
same route was given. Seizures lasting P20 min was managed
according to local guidelines; usually IM paraldehyde
(0.2 ml/kg) followed by IV phenobarbitone (10 mg/kg) then
by a loading dose of IV phenytoin (18 mg/kg) as necessary,
in 10-min intervals.
Consent was given in accordance with the Code of Federal
Regulations (Title 21) for clinical research in emergency set-
tings.34 Convulsing children were randomised and treated
and guardians were kept informed throughout. Once the child
was stable and all seizures had ceased, formal consent was
sought. If consent was refused no further information was
collected.
The College of Medicine Ethics Committee approved the
study (COMREC P03/07/499) and it was registered with
Clinical Trials.gov (NCT0343096).
The primary endpoint was the number of seizures that
stopped (cessation of all visible seizure activity) within (6)
10 min of receiving lorazepam.28 Secondary outcomes were
frequency of side effects, need for additional drugs to termi-
nate the seizure, seizure recurrence within 24 h, length of sei-
zure, time from drug administration to seizure cessation, and
outcome at discharge. Clinically signiﬁcant adverse events
were reported.
All clinical staff were trained six-monthly in the study pro-
tocol. Weight-dosing charts were available in every clinical
area.
122 S. Lissauer et al.We anticipated that lorazepam by any route would halt sei-
zureswithin 10 min in 75%of children.30 Sample size calculations
assumed this rate and a 10% non-inferiority limit. Thus, 293
patientswere required in each group tohave 80%power to accept
non-inferiority using a signiﬁcance level of 2.5%.
The predeﬁned stopping criterion was an absolute differ-
ence of 30% in the number of seizures controlled within
10 min between the groups. Interim analyses were carried out
after 100 and 400 recruitments, and then a year later, after
which the study was stopped.
Pre-study computer-generated randomisation was in blocks
of 10 within two strata – ‘IV access’ already established or ‘no
IV access’. Treatment allocations were sealed in identical
envelopes marked with consecutive study numbers.
Investigators were masked to treatment allocation prior to
opening an envelope. Inpatients who already had IV access
were randomised to receive intravenous, intranasal or buccal
lorazepam in a 1:1:1 ratio. Children without IV access were ran-
domised to receive intravenous, intranasal or buccal in a 3:1:1
ratio to allow for failure to achieve IV access. If a child was ran-
domised to IV lorazepam, attempts to gain IV access were for a
maximum of 2 min. To prevent treatment delay should access
fail, children were randomised within a second stratum to
receive intranasal or buccal lorazepam in a 1:1 ratio.
Intention to treat and per-protocol statistical analyses were
done using STATA 9.0. Baseline characteristics were compared
by one-way ANOVA or Wilcoxon tests. Categorical variables
were compared by Pearson Chi-square or Fisher’s exact tests.
The Binomial regression model was used to obtain risk ratios
and 95% conﬁdence intervals. Analyses were considered signif-
icant at the a-level of 0.05, decided a priori. When multiple test-
ing was involved, the Bonferroni correction was used.
Analyses were in pre-speciﬁed subgroups: those withmalaria
parasitaemia, cerebral malaria (malaria parasitaemia and
Blantyre Coma Score 6 2), meningitis (cerebrospinal ﬂuid or
clinical diagnosis) and fever (>38 C, with or without malaria).
Children were observed until clinically stable. Oxygen and
bag-mask ventilation was given if there were noticeable
changes in colour, respiratory effort, or airway compromise.
All patients had axillary temperature measurement, blood test
for malaria, blood glucose level, and a full clinical assessment
with further investigations as appropriate. Demographic infor-
mation included past history and estimated seizure duration
prior to hospital arrival.Results
Recruitment was from June 2006 to January 2009 and stopped
when an interim analysis showed a difference in primary end-
point of >30% between the groups.
Figs. 1a and 1b show patient stratiﬁcation by intravenous
access prior to randomisation.
There were 454 seizures randomised in children without
intravenous access and 434 episodes in children with pre-
existing intravenous access. Overall 888 seizures were ran-
domised in 733 patients: 88 patients stopped convulsing with-
out treatment and were excluded from analysis. In 41 patients
lorazepam was given by a route to which they were not ran-
domised; 20 in the buccal, 17 in the intranasal and four in
the intravenous group. Analyses were by intention to treat
and per protocol. Thirty-seven patients were lost to followup or had incomplete data. The primary analysis included
761 seizure episodes; 252 in the buccal, 245 in the intranasal
and 264 in the intravenous group. Of these, 606 patients were
recruited once and 69 were recruited two to four times. Re-
recruits were shared equally between the treatment groups.
They were randomised as new cases. Follow-up was until dis-
charge or death.
Baseline characteristics are shown in Table 1. Seizures were
due to cerebral malaria or meningitis in 113/252 (45%) in the
buccal group, 95/245 (39%) in the intranasal group and
127/264 (48%) in the intravenous group. Time from start of
seizure to drug administration was similar in all groups.
Outcomes are shown in Table 2. Seizures stopped within
10 min of receiving lorazepam in 115/252 (46%) of the buccal,
139/245 (57%) of the intranasal, and 218/264 (83%) of the
intravenous group (p 6 0.01).
Similar outcomes were seen with protocol analyses. In the
buccal group, 130 (50%) seizures required a second dose of
lorazepam and a further 80 (30%) required additional drugs
to terminate the seizure. In the intranasal group, 99 (40%) sei-
zures required a second lorazepam dose and 56 (20%) required
additional drugs. In the intravenous group 46 (17.5%) seizures
required a second lorazepam dose and 23 (9%) required addi-
tional drugs. Meningitis, history of seizures and prior neuro-
logical deﬁcit predicted the need for a second dose of
lorazepam (Table 3).
A planned, secondary analysis of the remaining 129 episodes
without these children and adjusted for age, weight, and gender,
showednodifference in the primary outcome (presenting seizure
stopped within 10 min). There was no signiﬁcant difference in
seizure recurrence at 24 h between the groups.
Median seizure duration was longer in the buccal and intra-
nasal groups (buccal: median 20, min IQR 15–35, intranasal:
median 19, min IQR 10–31) than in the intravenous group
(median 12, min IQR 8–20) (Fig. 2), though time from seizure
identiﬁcation to drug administration was similar for all groups.
No child was reported to require bag-mask ventilation after
lorazepam administration.
On discharge, 10.6% (n= 78) of survivors had neurologi-
cal deﬁcits (10 were pre-existing) with no difference between
the treatment groups; there was no difference in mortality
(Table 2, p= 0.6). Mean total seizure duration was similar
for children who died or had neurological deﬁcit and the gen-
eral cohort.
In children with protracted febrile seizures (feverP 38 C
without cerebral malaria or meningitis), buccal lorazepam
was as effective as intranasal lorazepam (41/69; 60% vs.
40/66; 60%). Both routes were less effective than intravenous,
which stopped seizures in 10 min in 83% (52/63) of children
(p 6 0.01). In children with malaria parasitaemia (including
cerebral malaria), buccal lorazepam was as effective as intra-
nasal lorazepam (65/125; 52% vs. 63/104; 60% p= 0.24),
however both these routes were less effective than intra-
venous lorazepam (110/128; 86%). There was no difference
in mean length of hospital stay among the three groups
(4.1–4.5 days).
There were 392 patients with existing intravenous access.
They were more likely to have previously known idiopathic
epilepsy (11% vs. 18.2%; p< 0.01), previous neurological
deﬁcit (7.6% vs. 3.3%; p= 0.01), or meningitis (19.7% vs.
12.8%; p= 0.01). They had more prolonged pre-treatment
seizures [50 min (5–170) vs. 10 min (3–85) p< 0.01]. There
Figure 1a Flowchart of participants with existing intravenous access n= seizure episode.
Figure 1b Flowchart of participants with no existing intravenous access n= seizure episode.
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Table 1 Baseline characteristics of trial participants.
Buccal Intranasal Intravenous
Total 252 245 264
n (%) n (%) n (%)
Demographic characteristics
Age (months, median IQR) 22 (10.0–38.0) 24 (11.0–38.0) 26 (12.0–41.0)
Sex male 123 (49) 141 (57.5) 142 (54)
Sex female 125 (50) 101 (41) 119 (45)
Weight (kilograms, median IQR) 9.8 (7.4–12.0) 10 (8.0–12.2) 10.4 (8.0–12.1)
HIV positive 31 (12) 23 (9) 23 (9)
HIV status not known 148 (59) 165 (67) 183 (69)
Malaria parasite screen positive 125 (50) 104 (42) 128 (48)
Fever at presentation (P38 C) 122 (48) 104 (42) 129 (49)
Seizure duration before treatment (minutes, median IQR) 10.0 (7.0–40.0) 10.0 (6.0–62.0) 15.0 (6.0–128.5)
Time from seizure identiﬁcation to drug administration (minutes, median IQR) 6.0 (5.0–10.0) 6.5 (5.0–10.0) 5.5 (5.0–10.0)
Underlying diagnosis
Previously known idiopathic epilepsy 30 (12) 34 (14) 45 (17)
Previously known neurological abnormality 12 (5) 12 (5) 17 (6.5)
Febrile seizure § 69 (27) 66 (27) 73 (28)
Malaria D 125 (50) 104 (42) 128 (48.5)
Cerebral malaria c 64 (25) 59 (24) 90 (34)
Acute bacterial meningitis b 49 (19) 36 (15) 37 (14)
Head injury 0 (0) 4 (2) 4 (1.5)
Ingestion local traditional medicine 5 (2) 14 (6) 8 (3)
Note: §, Patients who were febrileP38 C at time of seizure but did not have cerebral malaria or bacterial meningitis; D, Malaria parasitemia on
thick blood ﬁlm; c, Positive malaria blood slide, persistent Blantyre Coma Scale <2; b, CSF suggestive of meningitis, with or without positive
culture. Clinical diagnosis n= 5, too unwell for lumbar puncture.
Table 2 Primary and secondary outcome measures analysed by intention to treat analysis.
Outcome measure Buccal Intranasal Intravenous P value
n= 252 n= 245 n= 264
n (%) n (%) n (%)
Presenting seizure stopped within 10 min 115 (46) 139 (57) 218 (83) <0.01
Risk ratio (95% CI) 3.14 (2.4–4.2) 2.46 (1.8–3.3) 1.0
Seizure receiving a second dose of lorazepam 130 (51.5) 99 (40) 46 (17) <0.01
Seizure requiring phenobarbitone, paraldehyde, or phenytoin 80 (32) 56 (23) 23 (9) <0.01
Seizure recurrence within 24 h 48 (19) 62 (25) 47 (18) 0.09
Time from seizure identiﬁcation to seizure cessation (minutes) median IQR 20 IQR 13–35 19 IQR 10–31 12 IQR 8–20 <0.01
Time from drug administration to seizure cessation (minutes) median IQR 12 IQR 5–25 10 IQR 5–20 5 IQR 2–9 <0.01
Died 39 (15.5) 46 (19) 47 (18) 0.6
Neurological deﬁcit 20 (8) 33 (13.5) 25 (9.5) 0.1
Note: n seizure episodes; CI conﬁdence interval; IQR interquartile range.
Table 3 Patient characteristics associated with requiring a second dose of lorazepam to terminate seizure activity.
Characteristic Second dose of lorazepam Odds ratio (95% CI)
Yes No
n (%) n (%)
History of epilepsy/seizures 59 (54) 50 (46) 1.81 (1.18–2.79)
History of neurological complications 25 (61) 16 (39) 2.30 (1.15–4.68)
History of meningitis 64 (52) 59 (48) 1.68 (1.11–2.52)
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seizure when stratiﬁed by the presence of existing intravenous
access.In those without pre-treatment IV access and randomised
to receive IV lorazepam, the probability of obtaining access
was 0.81.
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Figure 2 Kaplan Meir curves representing seizure duration
following lorazepam (excluding those who continued to seize for
>1 h after administration of lorazepam (n= 30)).
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The study was stopped early as there was a larger than antic-
ipated difference between the groups, with IV lorazepam suc-
cessfully terminating 83% of seizures, and IN and buccal
terminating 57% and 46%, respectively. We had predicted sei-
zure termination with IV lorazepam as 60–90%14,35–38 and
with IN as 75%.30 Although prior experience with buccal lor-
azepam is limited, clinical33 and pharmacokinetic studies39
suggest it would be efﬁcacious. However, non-inferiority was
not proven in this study.
The IN dose (100 lg/kg) was based on a previous study in a
comparable population with the same primary outcome,30 and
pharmacokinetic data from adults.31 We decided not to
increase the dose due to the risk of respiratory depression
and confusion between the study arms with different dosing.
The efﬁcacy of IN lorazepam was comparable to that of buccal
midazolam16,17 and could be a useful drug route for pre-
hospital use or when IV access is difﬁcult.
Buccal and intranasal lorazepam were equally effective for
protracted febrile seizures and malaria. By 20 min, buccal lora-
zepam had stopped 60% of seizures and remained effective over
24 h. Oral or sublingual lorazepam are more slowly absorbed
than IVbut they are completely absorbed39 and pharmacokinet-
ically efﬁcacious. In a small paediatric study, sublingual loraze-
pam (n= 10) doses of 0.05–0.15 mg/kg controlled serial
seizures.33 We opted to give 100 lg/kg bucally for safety con-
cerns. This may have been insufﬁcient (compared to IV and
IN) because of slower absorption and possible loss by drooling.
Additional drugs were needed to terminate seizures in 30%
of the buccal, 20% of the IN and 9% of the IV groups. The IV
results are comparable to other studies.35 Meningitis, neuro-
logical deﬁcit, and known idiopathic epilepsy predicted the
need for a second dose of lorazepam. Seizures were longer in
the buccal and intranasal groups. Intravenous drug delivery
was not delayed as 80% of access attempts were successful.
This supports the use of IV lorazepam as ﬁrst line treatment
in most settings. We had been concerned that children with
existing IV access would be different (sicker), and randomised
them separately. However, there was no difference in time
taken to stop seizures in this group. Seizure duration was dif-
ﬁcult to record accurately for many children from the commu-
nity/local health centres.
Despite longer seizures in the buccal and IN groups,
there was no increase in neurological sequelae or death.Sequelae were diagnosed clinically and subtle deﬁcits may
have been overlooked. The incidence of neurological deﬁcit
and death (in this setting) is comparable to that of other
studies.16,30
No child required assisted ventilation. In a previous study
in this setting, IN lorazepam caused a temporary drop in oxy-
gen saturations in 2/80 children and none required additional
support.30 Ventilation is more commonly necessitated by pro-
longed seizure and underlying diagnosis than by benzodi-
azepine associated respiratory compromise.35,40
Though additional lorazepam doses were required to con-
trol seizures in the buccal and intranasal groups there was
no difference in 24-h seizure recurrence. Buccal midazolam is
associated with 40% recurrence in a similar setting,16 although
reports suggest that the intramuscular route may reduce break-
through seizures.35
Subgroup analysis showed that in malaria-induced seizures,
buccal lorazepam was as efﬁcacious as IN lorazepam. Around
half the children had malaria, and a quarter had cerebral
malaria. Cerebral malaria causes seizures in 15–50% of chil-
dren in sub-Saharan Africa2,30 and benzodiazepines are vari-
ably effective.16,41 Lorazepam was equally effective in
treating seizures with or without malaria and could be a drug
of choice.
The efﬁcacy of intravenous lorazepam has been estab-
lished in several trials.14,37,38 Our buccal and intranasal doses
were based on previous studies,30,33 and may have been too
low. There were some unexplained protocol violations and
bias may have occurred by re-recruiting patients who re-
seized, though analysis without these patients showed no
difference.Conclusion
Intranasal and buccal lorazepam are less effective than IV lor-
azepam as ﬁrst line treatment for acute seizures but may be
useful in children without or with difﬁcult IV access. Studies
comparing the use and dose of lorazepam with other anticon-
vulsants when IV access is difﬁcult are important.Author contribution
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